Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 8/20 | 0.47 |
| ▸ | BCHE | P06276 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6450091 | 0.89 | RAB9A (1.00) | RAB9AKMT2ANPSR1GAAALDH1A1 | |
| SCHEMBL2542317 | 0.81 | MEN1 (0.56) | RAB9AKMT2AMEN1ACHEBCHE | |
| P-Tolyl Dimethylcarbamate SCHEMBL360147 | 0.81 | RAB9A (0.83) | RAB9AKMT2ANPSR1GAAALDH1A1 | |
| 4-Chlorophenyl Dimethylcarbamate SCHEMBL11300470 | 0.79 | RAB9A (0.79) | RAB9AKMT2ANPSR1GAAALDH1A1 | |
| SCHEMBL9203037 | 0.79 | RAB9A (0.79) | RAB9AKMT2ANPSR1GAAALDH1A1 | |
| SCHEMBL9301148 | 0.79 | RAB9A (0.79) | RAB9AKMT2ANPSR1GAAALDH1A1 | |
| SCHEMBL15139541 | 0.79 | RAB9A (0.79) | RAB9AKMT2ANPSR1GAAALDH1A1 | |
| SCHEMBL2531879 | 0.79 | MEN1 (0.81) | RAB9AKMT2ATSHRMEN1ACHE | |
| Phenyl Dimethylcarbamate SCHEMBL491227 | 0.78 | RAB9A (0.78) | RAB9AKMT2ANPSR1GAAALDH1A1 | |
| SCHEMBL28376845 | 0.78 | RAB9A (0.76) | RAB9AKMT2ANPSR1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593425-B1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS INC (US) | 2018-10-17 | — | — | EP | claimed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | claimed |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-18 | — | — | US | claimed |
| EP-2593425-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | Agios Pharmaceuticals, Inc. (US) | 2013-05-22 | — | — | EP | claimed |
| WO-2012009678-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | WO | claimed |
| US-7101855-B2 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2006-09-05 | — | — | US | claimed |
| US-20060004019-A1 | Steroid sparing agents and methods of using same | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2006-01-05 | — | — | US | claimed |
| EP-1612215-A1 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2006-01-04 | — | — | EP | claimed |
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| US-20030027771-A1 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-02-06 | — | — | US | claimed |
| EP-1144435-A2 | PYROGLUTAMIC ACID DERIVATIVES AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2001-10-17 | — | — | EP | claimed |
| WO-2000043413-A2 | PYROGLUTAMIC ACID DERIVATIVES AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | claimed |
| EP-2593425-B1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2593425-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | Agios Pharmaceuticals, Inc. (US) | 2013-05-22 | — | — | EP | disclosed |
| WO-2000043413-A2 | PYROGLUTAMIC ACID DERIVATIVES AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| US-5614498-A | OLIGOPEPTIDES, BRONCHDILATORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1997-03-25 | — | — | US | disclosed |
| US-5496928-A | Endothelin antagonistic substance | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1996-03-05 | — | — | US | disclosed |
| EP-0555537-A2 | Endothelin antagonistic substance | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | RAB9A 1278/4885KMT2A 234/4885NPSR1 4865/4885 |
| US-20060004019-A1 | Steroid sparing agents and methods of using same | IL5, FCER2, CD40 | RAB9A 2549/4885KMT2A 1388/4885NPSR1 4217/4885 |
| US-20030027771-A1 | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | RAB9A 3815/4885KMT2A 795/4885NPSR1 4524/4885 |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | RAB9A 1278/4885KMT2A 234/4885NPSR1 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.